Preferred Name |
lisinopril |
|
Synonyms |
Zestril |
|
Definitions |
An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril, a synthetic peptide derivative, specifically and competitively inhibits ACE, which results in a decrease in the production of the potent vasoconstrictor angiotensin II and, so, diminished vasopressor activity. In addition, angiotensin II-stimulated aldosterone secretion by the adrenal cortex is decreased which results in a decrease in sodium and water retention and an increase in serum potassium. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29159" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29159" NCI Thesaurus) |
|
ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000658710 |
|
altLabel |
Zestril Prinivil |
|
CAS Registry |
83915-83-7 |
|
cui |
C0701176 C0678140 C0065374 |
|
DATE FIRST PUBLISHED |
2009-11-02 |
|
Date last modified |
2009-11-04 |
|
definition |
An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Lisinopril, a synthetic peptide derivative, specifically and competitively inhibits ACE, which results in a decrease in the production of the potent vasoconstrictor angiotensin II and, so, diminished vasopressor activity. In addition, angiotensin II-stimulated aldosterone secretion by the adrenal cortex is decreased which results in a decrease in sodium and water retention and an increase in serum potassium. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C29159" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C29159" NCI Thesaurus) |
|
LT |
TRD |
|
NCI ID |
C29159 |
|
notation |
CDR0000658710 |
|
ORIG STY |
Drug/agent |
|
prefLabel |
lisinopril |
|
tui |
T116 T121 |